SG11202102518VA - Pharmaceutical composition for controlled release of weak acid drugs and uses thereof - Google Patents

Pharmaceutical composition for controlled release of weak acid drugs and uses thereof

Info

Publication number
SG11202102518VA
SG11202102518VA SG11202102518VA SG11202102518VA SG11202102518VA SG 11202102518V A SG11202102518V A SG 11202102518VA SG 11202102518V A SG11202102518V A SG 11202102518VA SG 11202102518V A SG11202102518V A SG 11202102518VA SG 11202102518V A SG11202102518V A SG 11202102518VA
Authority
SG
Singapore
Prior art keywords
pharmaceutical composition
controlled release
weak acid
acid drugs
drugs
Prior art date
Application number
SG11202102518VA
Inventor
Pei Kan
Yi Fong Lin
Ko Chieh Chen
Original Assignee
Pharmosa Biopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmosa Biopharm Inc filed Critical Pharmosa Biopharm Inc
Publication of SG11202102518VA publication Critical patent/SG11202102518VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/191Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202102518VA 2018-09-14 2019-09-12 Pharmaceutical composition for controlled release of weak acid drugs and uses thereof SG11202102518VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731101P 2018-09-14 2018-09-14
PCT/US2019/050769 WO2020056104A1 (en) 2018-09-14 2019-09-12 Pharmaceutical composition for controlled release of weak acid drugs and uses thereof

Publications (1)

Publication Number Publication Date
SG11202102518VA true SG11202102518VA (en) 2021-04-29

Family

ID=69774640

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102518VA SG11202102518VA (en) 2018-09-14 2019-09-12 Pharmaceutical composition for controlled release of weak acid drugs and uses thereof

Country Status (13)

Country Link
US (1) US20200085741A1 (en)
EP (1) EP3849560A4 (en)
JP (2) JP7315982B2 (en)
KR (1) KR20210046018A (en)
CN (1) CN112672746A (en)
AU (1) AU2019339401B9 (en)
BR (1) BR112021003256A2 (en)
CA (1) CA3109851C (en)
IL (1) IL281217B2 (en)
MX (1) MX2021001820A (en)
SG (1) SG11202102518VA (en)
TW (1) TWI740205B (en)
WO (1) WO2020056104A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112826944B (en) * 2021-01-29 2023-08-15 台州职业技术学院 Ambrisentan inclusion compound and preparation method thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9203808A (en) * 1987-03-05 1992-07-01 Liposome Co Inc HIGH DRUG CONTENT FORMULATIONS: LIPID, FROM LIPOSOMIC-ANTINEOPLASTIC AGENTS.
DE4135193C1 (en) * 1991-10-22 1993-03-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
CA2161225C (en) * 1993-04-22 2003-07-01 Sinil Kim Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
WO1996025147A1 (en) * 1995-02-14 1996-08-22 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering liposome-loadable drugs
EP0825852B1 (en) * 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
CN1413575A (en) * 2001-10-25 2003-04-30 财团法人工业技术研究院 Liposome capable of coating high content hydrophobe material
US8518437B2 (en) 2001-11-13 2013-08-27 Celator Pharmaceuticals, Inc. Lipid carrier compositions with enhanced blood stability
EP1796653A2 (en) * 2004-07-26 2007-06-20 Actelion Pharmaceuticals Ltd. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
EP1793804A2 (en) * 2004-09-09 2007-06-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of liposomal glucocorticoids for treating inflammatory states
US20090047336A1 (en) * 2007-08-17 2009-02-19 Hong Kong Baptist University novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation
CN101744842A (en) * 2008-12-01 2010-06-23 马德林 Lipidosome Chinese traditional medicine membranous plaster
WO2010113983A1 (en) * 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Method for producing liposome composition
WO2012058483A1 (en) * 2010-10-28 2012-05-03 Pacira Pharmaceuticals, Inc. A sustained release formulation of a non-steroidal anti-inflammatory drug
IN2014DN10680A (en) 2012-06-29 2015-08-28 Microdose Therapeutx Inc
US20140220112A1 (en) * 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes
TWI656887B (en) * 2013-12-24 2019-04-21 國邑藥品科技股份有限公司 Liposomal suspension and its preparation method and application
US20160058705A1 (en) * 2014-08-28 2016-03-03 Jayakumar Rajadas Compositions and methods for treating cardiovascular and pulmonary diseases and disorders with apelin
CN106214641A (en) * 2016-08-22 2016-12-14 沈阳鑫泰格尔医药科技开发有限公司 A kind of liposome being applicable to water soluble drug and preparation method thereof
US11964050B2 (en) * 2017-07-24 2024-04-23 Pharmosa Biopharm Inc. Liposome compositions comprising weak acid drugs and uses thereof

Also Published As

Publication number Publication date
KR20210046018A (en) 2021-04-27
JP2023123843A (en) 2023-09-05
EP3849560A1 (en) 2021-07-21
CA3109851A1 (en) 2020-03-19
AU2019339401A1 (en) 2021-04-15
WO2020056104A1 (en) 2020-03-19
JP7315982B2 (en) 2023-07-27
CA3109851C (en) 2024-02-20
CN112672746A (en) 2021-04-16
IL281217B2 (en) 2024-05-01
TW202023530A (en) 2020-07-01
EP3849560A4 (en) 2022-06-08
IL281217B1 (en) 2024-01-01
MX2021001820A (en) 2021-04-28
TWI740205B (en) 2021-09-21
JP2021535922A (en) 2021-12-23
US20200085741A1 (en) 2020-03-19
AU2019339401B2 (en) 2022-10-27
AU2019339401B9 (en) 2022-11-03
BR112021003256A2 (en) 2021-05-18
IL281217A (en) 2021-04-29

Similar Documents

Publication Publication Date Title
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL279464A (en) Pharmaceutical formulation of odevixibat
EP3694832A4 (en) Extended release pharmaceutical formulation and methods of treatment
EP3570927A4 (en) Medical products and methods configured for controlled release of nitrous oxide
EP3556369A4 (en) Olaparib oral sustained and controlled release pharmaceutical composition and uses thereof
EP3498279A4 (en) Pharmaceutical composition comprising amodiaquine and anti-diabetes drug as effective ingredient for prevention or treatment of diabetes
PL3187175T3 (en) Supplementary therapeutic formulations for the sequential or separate administration of butyric acid and probiotics
EP3380525A4 (en) Pharmaceutical formulations and methods of use thereof
IL279397A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
EP3290034A4 (en) Use of trimethazine in preparation of drugs for preventing and treating liver diseases
EP3498280A4 (en) Administration and dosage of therapeutic agent for endometriosis
DK3168214T3 (en) SUBSTITUTED 2-THIOXO-IMIDAZOLIDIN-4-ONES AND SPIRO ANALOGUES THEREOF, ACTIVE ANTI-CANCER INGREDIENT, PHARMACEUTICAL COMPOSITION, MEDICINE PREPARATION, PROCEDURE FOR TREATMENT OF PROSTATANCES
EP3485887A4 (en) Injectable pharmaceutical composition of tecovirimat and preparation method thereof
EP3368010A4 (en) Solid dosage form immediate drug release and apparatus and method for manufacture thereof
IL280083A (en) Pharmaceutical dosage form which can be administered orally and has modified release
SG10202008700VA (en) α-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF
HK1245094A1 (en) Pharmaceutical composition for treatment of depression and preparation method thereof
IL281217A (en) Pharmaceutical composition for controlled release of weak acid drugs and uses thereof
EP3522889A4 (en) Delayed release pharmaceutical composition of pantoprazole and process for preparation thereof
EP3532052A4 (en) Design and composition of cell-stabilized pharmaceutical formulations
EP3880183A4 (en) Pharmaceutical preparation of fruquintinib and use thereof
EP3468540A4 (en) Pharmaceutical compositions and methods for treatment of pain
EP3291798A4 (en) A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof
IL271596A (en) Compositions for drug delivery and methods of use thereof
SG11202011045VA (en) Pharmaceutical composition for controlled release of treprostinil